Emerald Advisers’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.7M | Buy |
1,038,049
+139,859
| +16% | +$1.58M | 0.43% | 89 |
|
|
2025
Q1 | $10.4M | Buy |
898,190
+62,140
| +7% | +$717K | 0.47% | 81 |
|
|
2024
Q4 | $7.08M | Buy |
836,050
+62
| +0% | +$525 | 0.27% | 103 |
|
|
2024
Q3 | $9.68M | Buy |
835,988
+192,091
| +30% | +$2.22M | 0.37% | 88 |
|
|
2024
Q2 | $7.59M | Sell |
643,897
-27,279
| -4% | -$321K | 0.32% | 101 |
|
|
2024
Q1 | $7.96M | Buy |
+671,176
| New | +$7.96M | 0.32% | 102 |
|
|
2021
Q4 | – | Sell |
-304,113
| Closed | -$5.31M | – | 287 |
|
|
2021
Q3 | $5.31M | Sell |
304,113
-70,520
| -19% | -$1.23M | 0.19% | 115 |
|
|
2021
Q2 | $8.98M | Sell |
374,633
-22,650
| -6% | -$543K | 0.33% | 105 |
|
|
2021
Q1 | $10.2M | Buy |
+397,283
| New | +$10.2M | 0.37% | 104 |
|